Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CDRE vs MYO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDRE Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

CDRE Overall Winner 6-Pillar Tally: CDRE 5 – 1 MYO Matrix Metrics: CDRE 9 – 1 MYO

As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDRE carries a Unified Composite Score of 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin).

  • Defensive Composite Rating Caution: Although CDRE compares more favorably head-to-head, both CDRE (39.6/100 SELL) and MYO (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: CDRE trades in a Neutral technical trend (SURGE options phase, RSI 42.7); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDRE vs MYO
CDRE NYSE Head-to-Head Winner
Cadre Holdings, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$29.45
-3.63% 1D
Market Cap $1.3B
TTM Revenue $733M
Forward P/E 18.5x
Beta / 30D Vol 0.87β · 42% Vol
Unified Composite Score
39.6 / 100 SELL
Tech 15.0 Fund 40.0 Flow 55.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.7 · SMA20: $31.80 · SMA50: $28.53
MYO NYSE American
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32

6-Pillar Scorecard Institutional Category Breakdown (CDRE 5 – 1 MYO)

Columns: Metric · CDRE · MYO
1. Valuation Multiples CDRE
Forward P/E 18.5x N/M
Trailing P/E 33.6x N/M
PEG Ratio N/M N/M
EV / Revenue 2.2x 0.9x
2. Growth & Scale CDRE
Revenue Growth (YoY) +30.2% +22.2%
Earnings Growth (YoY) +37.5% +0.0%
TTM Revenue (USD) $733M $46M
Market Cap $1.3B $33.7M
3. Profitability & Quality CDRE
Gross Margin 42.8% 70.1%
Operating Margin 12.5% -21.8%
Net Profit Margin 5.6% -33.1%
Return on Equity (ROE) 11.6% -173.5%
4. Balance Sheet & Cash Flow CDRE
Cash Generation (TTM) $76M -$9.1M
Cash Flow Margin 10.4% -20.0%
Net Cash / Leverage $330M Net Debt (1.08x D/E) $8.9M Net Debt (3.44x D/E)
Dividend Yield 1.24% None (0.00%)
5. Options & Positioning MYO
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 47.3% (2nd %ile) 266.0% (81st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CDRE
OpEx & R&D Intensity 30.3% of Rev ($222M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Aerospace & Defense Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDRE (9) vs MYO (1)
Institutional Metric CDRE MYO Criterion Row Edge
Market Capitalization
Scale
$1.3B $33.7M Larger Scale CDRE
Trailing P/E Ratio
Valuation
33.6x N/M Lower Multiple CDRE
Forward P/E Ratio
Valuation
18.5x N/M Lower Multiple CDRE
Revenue Growth (YoY)
Growth
+30.2% +22.2% Higher Growth CDRE
Operating Margin (TTM)
Profitability
12.5% -21.8% Higher Margin CDRE
Net Profit Margin
Profitability
5.6% -33.1% Higher Margin CDRE
Return on Equity (ROE)
Capital Efficiency
11.6% -173.5% Higher ROE CDRE
52-Week Range Position
Momentum
22% ($24–$49) 16% ($1–$2) Stronger Trend CDRE
Beta / 30D Volatility
Risk Regime
0.87β · 42% Vol 2.22β · 107% Vol Lower Realized Risk CDRE
Unified Institutional Score
Composite Signal
39.6 / 100 (SELL) 40.1 / 100 (SELL) Higher Composite MYO
Trailing 12M Revenue (USD)
Operating Scale
$733M $46M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
42.8% 70.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.2x EV/Rev N/M PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$76M ($330M Net Debt (1.08x D/E)) -$9.1M ($8.9M Net Debt (3.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDRE +33.49 pp
CDRE: -0.03% · MYO: -33.52%
3M Horizon CDRE +30.68 pp
CDRE: -10.97% · MYO: -41.65%
6M Horizon CDRE +19.18 pp
CDRE: -2.84% · MYO: -22.02%
1Y Horizon MYO +38.68 pp
CDRE: -26.38% · MYO: +12.3%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CDRE Revenue MYO Revenue CDRE Op. Margin MYO Op. Margin Margin Leader
FY2018 N/A $0M N/A -430.8% MYO
FY2019 N/A $0M N/A -281.3% MYO
FY2020 $400M $10M 12.3% -138.5% CDRE
FY2021 $430M $10M 12.1% -74.1% CDRE
FY2022 $460M $20M 3.7% -68.6% CDRE
FY2023 $480M $20M 11.7% -42.8% CDRE
FY2024 $570M $30M 11.8% -19.1% CDRE
FY2025 $610M $40M 11.0% -35.2% CDRE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDRE SURGE
9d in phase · OBV DISTRIBUTION
Current IV 47.3%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact CDRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDRE Moat Profile Cyclical / Execution-Driven Positioning
Aerospace & Defense Operator
Competes within the Aerospace & Defense value chain with $1.3B market capitalization and 12.5% operating margin.
OpEx & R&D Reinvestment 30.3% of Rev ($222M)
90D Engineering Disclosures 0 Published
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDRE vs MYO Key Questions & Quantitative Answers

As of Nov 20, 2026, Cadre Holdings, Inc. (CDRE) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CDRE carries a Unified Composite Score of 39.6/100 (SELL) at $29.45 (18.5x Forward P/E, 12.5% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin). Defensive Composite Rating Caution: Although CDRE compares more favorably head-to-head, both CDRE (39.6/100 SELL) and MYO (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CDRE trades in a Neutral technical trend (SURGE options phase, RSI 42.7); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDRE leads the Growth & Scale pillar: CDRE posts +30.2% YoY revenue growth and +37.5% YoY earnings growth on $733M TTM revenue (42.8% gross margin, 12.5% operating margin), compared with MYO at +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CDRE cumulative revenue shifted +52.5% while MYO shifted +300.0%. In operating R&D and SG&A reinvestment, CDRE deploys 30.3% of Rev ($222M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MYO.

CDRE screens cheaper on headline valuation multiples. CDRE trades at 18.5x Forward P/E, 33.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (10.4% FCF margin), whereas MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDRE (11.6% ROE) versus MYO (-173.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CDRE carries 47.3% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.87β · 42% Vol realized risk). By comparison, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.